Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge has represented Inflexion in connection with the acquisition of Mecenat

 Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025

Vinge has advised the sellers in connection with the sale of Färskvaruhuset i Göteborg AB

 Färskvaruhuset i Göteborg AB is a Swedish nationwide supplier to the retail sector within meat and poultry as well as charcuterie and delicatessen products. The acquirer was the international food trading company BPI A/S, headquartered in Denmark.
January 13, 2025

Vinge has advised the seller in conjunction with the sale of Lundby Plåt Aktiebolag

 Lundby Plåt Aktiebolag provides services within sheet metal work. The acquirer was the Gothenburg based contracting and construction services company, Göfast Gruppen AB.
January 13, 2025